Drug Profile
TERN 201
Alternative Names: SSAO inhibitors - Terns Pharmaceuticals; TERN-201Latest Information Update: 10 May 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Terns Pharmaceuticals
- Class Antineoplastics; Hepatoprotectants; Small molecules
- Mechanism of Action AOC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
- Preclinical Solid tumours
Most Recent Events
- 01 Mar 2023 TERN 201 is available for licensing as of 01 Mar 2023. https://www.ternspharma.com/ 3781244
- 06 Jan 2023 Preclinical trials in Solid tumours in USA (unspecified route)
- 02 Sep 2022 Terns Pharmaceuticals completes the phase Ib AVIATION trial for Non-Alcoholic Steatohepatitis in USA (PO) (NCT04897594)